Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register
Janneke Anink(Boston Children's Hospital), Lisette W. A. van Suijlekom‐Smit(Erasmus MC - Sophia Children’s Hospital), Maryanne Dijkstra(Erasmus MC - Sophia Children’s Hospital), Marinka Twilt(University of Calgary), E. P. A. H. Hoppenreijs(Radboud University Nijmegen), Y. Koopman-Keemink(Juliana Kinderziekenhuis), François Prince(Hôpital du Sacré-Cœur de Montréal), Simone Gorter(University Medical Center Groningen), Marion A. J. van Rossum(Reade), R. ten Cate(Leiden University), M.H. Otten(Erasmus University Rotterdam)
Data Archiving and Networked Services (DANS)
October 31, 2014
Cited by 0
Related Papers
Anakinra as first‐line disease‐modifying therapy in systemic juvenile idiopathic arthritis: Report of forty‐six patients from an international multicenter series
|Arthritis & Rheumatism|2010|465
Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register
|Annals of the Rheumatic Diseases|2008|220
Sulfasalazine in the treatment of juvenile chronic arthritis: A randomized, double-blind, placebo-controlled, multicenter study
|Arthritis & Rheumatism|1998|217
Predictors of health‐related quality of life in children and adolescents with juvenile idiopathic arthritis: Results from a web‐based survey
|Arthritis Care & Research|2012|155